This video showcases a heavily modified 1961 Chevrolet Corvette C1 restomod built by Old Anville Speed Shop. The project combines the classic styling of the original Corvette with modern engineering ...

J’s Racing has launched a development project for the Honda Prelude, a returning nameplate that has drawn mixed reactions over its performance credentials. The new Honda Prelude's hybrid, auto-only ...

Data on investigational obexelimab and frexalimab, blood neurofilament light chain as a marker for treatment response, and benefits of ofatumumab are highlighted findings in relapsed-remitting ...

Announcing a new publication for Acta Materia Medica journal. Diacerein, an anthraquinone derivative, is emerging as a promising disease-modifying agent in rheumatoid arthritis (RA), because of its ...

The Urban Prepper shows how to magnetically modify an Altoids tin to create clever and practical prepper hacks. Trump declares national emergency at airports, will sign order instructing DHS to ...

Forbes contributors publish independent expert analyses and insights. Tiana Randall is a writer whose work intersects style and sports. The hesitation was understandable. We were already drowning in ...

As Immigration and Customs Enforcement (ICE) presence and operations in Minnesota have ramped up, some schools that closed as a precaution have reopened, while Minneapolis Public Schools (MSP) ...

Amyloid-targeted monoclonal antibodies are the first disease-modifying therapies (DMTs) approved for Alzhemier’s disease (AD). Aducanumab received accelerated approval by the FDA but was not fully ...

Pattern Energy Group, a provider of clean energy and transmission infrastructure, and Cordelio Power announced they have entered into a definitive agreement for Pattern Energy to acquire Cordelio ...

Ianalumab combined with eltrombopag significantly extends time to treatment failure and improves stable response rates in ITP patients relapsing after first-line steroids. The combination therapy ...

Potential disease-modifying targets of Alzheimer’s disease include (but not limited to) amyloid (A), tau (T), neurodegeneration (N), inflammation (I), vascular injury (V), and α-synuclein (S).

Please provide your email address to receive an email when new articles are posted on . In this Healio video, David G. Standaert, MD, PhD, discusses a plenary session on disease-modifying trials in ...